NC

Niklas Czeloth

Investment Manager - Boehringer Ingelheim Venture Fund

Frankfurt Rhine-Main Metropolitan Area

Invests in

Stages:

Locations:

  • Min Investment:

    $3,250,000.00
  • Max Investment:

    $17,000,000.00
  • Target Investment:

    $8,500,000.00

Work Experience

  • Chairman of the Board (Interim)

    2023

  • Director Board of Directors

    2023

2023

  • Chairman of the Board (Interim)

    2023

  • Director Board of Directors

    2023

  • Member of Boehringer Ingelheim´s Immunogenicity Expert Panel

    2014

  • Executive Director / Investment Manager - Boehringer Ingelheim Venture Fund

    2020

    Interest in early investment opportunities in immuno-oncology, regenerative medicine and anti-infectives. (Please describe scope of interaction in contact requests. Thank you!)

  • International Project Leader (Oncology, Retinopathy, CNS projects)

    2018 - 2020

    Project leadership for global drug development projects

  • Director / Head of Biosciences (Nonclinical / DMPK / Pharmacology) Biosimilars

    2014 - 2018

    Head of Bioanalysis/DMPK Biosimilar Programs Heading of non-clinical activities for Biosimilars Portfolio Serving as Head of Nonclinical for Biosimilar projects Pharmacology / Toxicology activities for the Biosimilars Business

  • Project Manager DMPK Biosimilars

    2013 - 2014

    Pharmacokinetics of monoclonal antibodies (biosimilarity trials, population PK) Responsibility for Bionalysis/DMPK (PK, ADA, nAb assays) Pharmacology of monoclonal antibodies (SPR, CDC, ADCC, effector functions, FcR, glycosylation) Immunogenicity Toxicological studies Translational research/devlopment Regulatory agenciy interactions

  • Director Board of Directors

    2020 - 2021

2008 - 2013

  • Leiter Pharmakologie Biotherapeutika

    2008 - 2013

    Associate Director Pharmacology Biotherapeutics. Expertise Preclinical Development, Immunology, ICH Guidelines, IMPD/IND preparation, Toxicology, PK/PD, Project management, Monoclonal Antibodies, Biotherapeutics, Flowcytometrie, Research Tregs, Collaboration Management.

  • Scientist

    2003 - 2007

    Scientist Immunology Basic Research Dendritic cells, T cells, Tregs, B cells, Cell Trafficking, S1P signalling. Expertise FACS, cell sorting, Immunofluorescence, Antibody production, labelling.basic immunology, RT-PCR.